Hormonal
GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with specific benefits on stroke and weight loss.
If you have Type 2 Diabetes and are at high risk for heart attack or stroke, ask your doctor about GLP-1 receptor agonists (like Victoza, Ozempic, or Trulicity). These medications have been proven to significantly reduce the risk of major cardiovascular events and stroke. They also promote weight loss, which is an added benefit. They are available as injections (daily or weekly) and in some cases, oral tablets.
The LEADER trial ... involving liraglutide ... showed an overall 13% reduction in the primary composite endpoint of 3-point MACE ... SUSTAIN-6 evaluated the efficacy of semaglutide ... showed a 24% reduction in the primary composite CVD outcome, including a 39% reduction in nonfatal stroke.
Why this rating
Based on large RCTs (LEADER, SUSTAIN-6, PIONEER-6).
Source
Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks
Nathan D. Wong · Canadian Journal of Physiology and Pharmacology · 2022
DOI 10.1139/cjpp-2022-0065
More from this paper
- SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with type 2 diabetes, regardless of baseline glycemic control.Strong
- Icosapent ethyl (pure EPA) reduces cardiovascular events in patients with Type 2 Diabetes and elevated triglycerides who are already on statin therapy.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →